References
- 1Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011; 26(12): 2226–31. DOI: 10.1002/mds.23828
- 2López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging. 2012; 29(2): 105–18. DOI: 10.2165/11598540-000000000-00000
- 3Zhang CQ, He BM, Hu ML, Sun HB. Risk of Valproic Acid-Related Tremor: A Systematic Review and Meta-Analysis. Front Neurol. 2020; 11:
576579 . DOI: 10.3389/fneur.2020.576579 - 4Rissardo JP, Fornari Caprara AL, Durante Í. Valproate-associated Movement Disorder: A Literature Review. Prague Medical Report. 2021; 122: 140–180. DOI: 10.14712/23362936.2021.14
- 5Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017; 44: 147–50. DOI: 10.1016/j.parkreldis.2017.09.011
- 6Alonso-Juarez M, Baizabal-Carvallo JF. Distinguishing features between valproate-induced tremor and essential tremor. Acta Neurol Scand. 2018; 138(2): 177–81. DOI: 10.1111/ane.12953
- 7Paparella G, Angelini L, De Biase A, Cannavacciuolo A, Colella D, Di Bonaventura C, et al. Clinical and Kinematic Features of Valproate-Induced Tremor and Differences with Essential Tremor. Cerebellum. 2021; 20(3): 374–83. DOI: 10.1007/s12311-020-01216-5
- 8Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004; 62(8): 1435–7. DOI: 10.1212/01.WNL.0000121228.32913.00
- 9Ristić AJ, Vojvodić N, Janković S, Sindelić A, Sokić D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006; 47(12): 2183–5. DOI: 10.1111/j.1528-1167.2006.00711.x
- 10Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007; 22(1): 130–3. DOI: 10.1002/mds.21188
- 11Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord. 2008; 23(13): 1825–9. DOI: 10.1002/mds.22098
- 12Chen W, Hopfner F, Becktepe JS, Deuschl G. Rest tremor revisited: Parkinson’s disease and other disorders. Transl Neurodegener. 2017; 6: 16. DOI: 10.1186/s40035-017-0086-4
- 13Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord. 2013; 19(8): 758–60. DOI: 10.1016/j.parkreldis.2013.03.016
- 14Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry. 2005 Sep; 76(9): 1211–6. DOI: 10.1136/jnnp.2004.045237
- 15Brugger F, Bhatia KP, Besag FM. Valproate-Associated Parkinsonism: A Critical Review of the Literature. CNS Drugs. 2016; 30(6): 527–40. DOI: 10.1007/s40263-016-0341-8
- 16Lan L, Zhao X, Jian S, Li C, Wang M, Zhou Q, Huang S, Zhu S, Kang H, Kirsch HE. Investigation of the risk of valproic acid-induced tremor: clinical, neuroimaging, and genetic factors. Psychopharmacology (Berl). 2022; 239: 173–184. DOI: 10.1007/s00213-021-06004-5
- 17Silva MF, Aires CC, Luis PB, Ruiter JP, L IJ, Duran M, Wanders RJ, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008; 31(2): 205–16. DOI: 10.1007/s10545-008-0841-x